Roche Statement Regarding the Cochrane Report on Tamiflu
Today, Roche has issued the following statement regarding the results of the Cochrane report:
"Roche fundamentally disagrees with the overall conclusions of the Cochrane Acute Respiratory Infections Group’s (ARI) report on Tamiflu. We firmly stand by the quality and integrity of our data, reflected in decisions reached by 100 regulators across the world and subsequent real-world evidence demonstrating that Tamiflu is an effective medicine in the treatment and prevention of influenza.[1,2]
Influenza is a serious and at times life-threatening infection.[3] Cochrane’s report fails to take into account the totality of data available for Tamiflu, including only 20 out of 77 clinical trials available to them and excluding real-world data from observational trials. The result is a misrepresentation of the efficacy and safety of an established influenza medicine, undermining global public health consensus.
We welcome third-party research, and are dedicated to sharing clinical data for our medicines in the interest of advancing science. However we do not consider the Cochrane ARI Group, who have identified themselves as inexperienced in dealing with large quantities of information within clinical study reports,[4] to be an authority on the value of neuraminidase inhibitors. Roche believes it is important that public health bodies and influenza experts provide their opinion on this review, alongside the totality of Tamiflu data, before any conclusions are drawn.
Patient-level data specifically made available to Cochrane has also not been taken into consideration for this review. This data allows greater precision in estimating clinical outcomes and has many statistical advantages,[5] as compared to the study-level data used by Cochrane in their review. A recent study of patient-level data from nearly 30,000 patients in a pandemic setting, published in The Lancet Respiratory Medicine, drew different conclusions, showing that treatment with neuraminidase inhibitors, such as Tamiflu, was associated with a reduction in the risk of death by 19% when compared with no treatment.[6]
Other trials and real-world data from seasonal influenza and the 2009–2010 flu pandemic have also shown that Tamiflu is effective in reducing the severity and duration of symptoms in those infected with flu.[7-14] Tamiflu, having been reviewed and approved by regulatory authorities in over 100 countries, has a well-understood safety profile and has been taken by over 130 million patients worldwide.[1,2] As with all of our medicines, we continuously monitor safety data related to the use of Tamiflu and this information is routinely provided and reviewed by regulatory authorities.
Roche stands behind the abundance of data for Tamiflu as a treatment option recommended by public health agencies worldwide, including the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO).
References
1.Roche data on file RXUKDONF00349. 2014
2.www.medicines.org.uk/emc/document.aspx?documentid=10446 (Last accessed: March 2014).
3.www.cdc.gov/flu/about/disease/symptoms.htm (Last accessed: March 2014)
4.Jefferson T, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014;348:g2545 doi: 10.1136/bmj.g2545
5.Kelley GA, et al. Statistical models for meta-analysis: a brief tutorial, World J Methodol 2012 August 26; 2(4): 27-32.
6.Muthuri SG, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in hospitalised influenza A (H1N1)pdm09 patients: an individual participant data meta-analysis. Lancet Respiratory Medicine. Published online March 19, 2014.
7.Kaiser, L, et al. Archives of Internal Medicine. 2003;163:1667−1672
8.Rodriguez A, et al. J. Antimicrobial Chemother 2011 ; 66;114011–49
9.Lee N, et al. J Infect Dis 2011;203:1739–1747
10.Hiba V, et al. J Antimicrob Chemother 2011;66:1150–1155
11.Nordstrom et al. Current Medical Research and Opinion 2005; 21:5;761-768 Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir
12.Orzeck et al. Clinical Therapeutics 2007; 29:10;224622–55
13.Nicholson, K, et al. Lancet 2000;355:1845–1850.
14.Treanor, J, et al. Journal of the American Medical Association. 2000;283:1016−1024.
Related News
-
News Updated – Changing abortion pill access according to the US FDA and Supreme Court
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug. -
News CPHI North America 2024 – From the Floor
Welcome to Philly! CPHI North America once again graces the Philadelphia Convention Center, 7–9 May 2024. -
News Drug Patent Expiries: a steep cliff or opportunity for innovation?
The pharmaceutical industry faces a patent cliff together in the years leading up to 2030. Learn what this means for drug pricing, their outsourcing partners, and drug innovation of the future. -
News A Day in the Life of a President and Chief Scientific Officer
We are continuing to get to know the people working day-to-day behind the pharma companies shaping the industry, the ones who keep the wheels turning and ultimately bring better healthcare to the population; we are talking to the individuals at the hea... -
News Gerresheimer predicts weight-loss drug deals to account for 4% of yearly growth
Dietmar Siemssen, CEO of German primary packaging manufacturer Gerresheimer, states that approximately 4% of the company’s revenue growth each year to come from deals with drugmakers of weight loss and diabetes products, particularly GLP-1 class ... -
News LEAP-ing into the future of pharma – the CPHI Middle East Vision
On March 6, 2024, the CPHI team hosted the Future of Pharma Forum at LEAP 2024, Saudi Arabia’s premier destination for tech leaders and innovators to meet and collaborate. -
News Informa Markets International Women’s Day Panel Discussion
On March 7, 2024, the Informa Markets Amsterdam office hosted an International Women’s Day Breakfast and Panel Discussion to celebrate the women who drive the B2B events industry forward, including members of the CPHI team. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance